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doi:10.1016/j.jtcvs.2007.11.007Objectives: The aim of this study was to evaluate, by immunohistochemical analysis,
the protein expression of b-catenin and p53 in resected esophageal squamous cell
carcinoma specimens. The clinical relevance and prognostic significance of the
expression of these proteins were also analyzed.
Methods: Immunohistochemistry was performed on paraffin-embedded tissue speci-
mens from 68 resected esophageal squamous cell carcinoma tumor specimens to
detect the expression of b-catenin and p53. The correlation between the results of
immunoexpression and the clinicopathologic parameters and patient survival was
processed statistically.
Results: Reduced membranous b-catenin expression was noted in 43 (63.2%) of 68
tumor specimens. Increased expression of p53 was observed in 43 (63.2%) of 68 spec-
imens. Reduced membranous b-catenin protein expression was associated with the
presence of distant metastasis (P 5 .006). Patients with reduced membranous
b-catenin expression had a worse prognosis than patients with normal membranous
b-catenin expression (P 5 .005). Patients with combined increased p53 and reduced
membranous b-catenin protein expression had the worst prognosis (P 5 .012). In
a multivariate survival analysis, reduced membranous b-catenin expression and nodal
involvement were independent prognostic factors (P 5 .004 and .019, respectively).
Conclusions: Immunohistochemical analysis revealed that reduced membranous
b-catenin protein expression was associated with the presence of distant metastasis
and a poor prognosis in patients with esophageal squamous cell carcinoma. Combined
increased p53 and reduced membranous b-catenin protein expression indicated a very
poor prognosis in patients with esophageal squamous cell carcinoma. Further inves-
tigation is needed to understand the roles of b-catenin and p53 in the tumorigenesis
and metastasis of esophageal squamous cell carcinoma.
E
sophageal squamous cell carcinoma (ESCC) is associated with poor patient
survival despite aggressive treatments. The 5-year survival in patients with
ESCC is usually approximately 20% to 25% after standard esophagectomy.
Many clinicopathologic variables, including the tumor invasion depth, the lymph
node involvement, lymphovascular invasion, and distant metastasis, have been exam-
ined in patients with ESCC as aids to predict the prognosis.1 Some molecular changes
have also been investigated to elucidate the tumorigenesis of ESCC. Recently,
b-catenin has drawn much attention because its connection to tumorigenesis has
been reported in many types of gastrointestinal cancers, including colorectal, gastric,
and esophageal cancers.2 The multifunctional b-catenin plays crucial roles in signal
transduction and maintenance of cell–cell adhesion.3,4 Under normal circumstances,
the cytoplasmic b-catenin level is kept low through a large multiprotein destruction
complex. Within this complex, b-catenin is phosphorylated by casein kinase Ia/gly-
cogen synthase kinase 3b (GSK3b), ubiquitinated by b-transducin-repeat–containing
protein, and subsequently degraded in proteasomes.5 Either b-catenin gene mutation
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or dysfunction of the destruction complex may lead to accu-
mulation of cytoplasmic b-catenin. Should b-catenin inap-
propriately enter the nucleus, it forms a complex with T
cell–specific factor/lymphoid enhancer binding factor protein
and activates aberrant transcription after binding to DNA.3-5
In addition, b-catenin also links E-cadherin at the cell mem-
brane and associates with the actin cytoskeleton through a-
catenin.6 In a multi-institutional study enrolling 416 patients
with ESCC, the investigators found that loss of E-cadherin
expression was associated with a poor prognosis in patients
with ESCC.7 Reduced membranous b-catenin expression
may also downregulate the E-cadherin–catenin complex,
which may disrupt the integrity of cell architecture and con-
tribute to enhanced tumor cell migration, leading to invasion
and metastasis.3,8 Deregulated b-catenin, either increased
cytoplasmic levels or reduced membranous levels, would
contribute to tumorigenesis by inappropriate transcription
of target genes and the loss of cell–cell adhesion.9
A possible cross-talk between the b-catenin and p53 path-
ways during cancer progression has long been suggested,
most notably in human colorectal cancers.10,11 Activation
of p53 occurs in response to a stress signal and leads to either
cell cycle arrest or cellular apoptosis.11 The functional p53
protein safeguards against deregulated cells by eliminating
cells with damaged genomes as well as facilitating the repair
of such damage.12 Authors of some studies have demon-
strated that b-catenin levels can induce the p14ARF gene,
which negatively regulates MDM2 and results in higher
p53 levels.10,11 An activated p53 protein, in turn, positively
regulates the transcription of Siah, Axin, and GSK3b
proteins, which subsequently act to degrade the b-catenin
protein.13-15
There are few studies in the literature in which the rela-
tionship between b-catenin and p53 protein expression in
ESCC is investigated. In this study, we evaluated the protein
expression of b-catenin and p53 in resected ESCC specimens
by using immunohistochemical analysis. The clinical rele-
vance and prognostic significance of these protein expres-
sions were also analyzed.
Patients and Methods
Patients
Tumor specimens were obtained from 68 patients with ESCC who
underwent subtotal esophagectomy and reconstruction through
a retrosternal approach between 1996 and 2000 at Taipei Veterans
General Hospital. There were 2 women and 66 men. The mean
age was 65 years (range 36–83 years). None of these patients
received chemotherapy or radiotherapy preoperatively. The patho-1030 The Journal of Thoracic and Cardiovascular Surgery c Mlogic tumor stage was determined according to the TNM classifica-
tion.16 The clinicopathologic data, including gender, age, depth of
tumor invasion, lymph node involvement, and presence of distant
metastasis, were collected retrospectively. Postoperative adjuvant
therapy was given in patients with lymph node metastasis or in
patients who were found to have tumor recurrence or metastasis
during the follow-up period. The survival data were obtained from
the Cancer Registry Database in the Taipei Veterans General Hospi-
tal. Overall patient survival, defined as the time from operation to
death, was used as a measure of prognosis. This study was approved
by the Institutional Review Board in the Taipei Veterans General
Hospital.
Immunohistochemical Staining
Immunohistochemical staining was performed on 3-mm–thick sec-
tions of formalin-fixed, paraffin-embedded tissue. After deparaffini-
zation and rehydration, all sections were treated with microwaves in
10 mmol/L citrate buffer (pH 6.0) for 10 minutes at 121C for
antigen retrieval. To block endogenous peroxidase activity, we
immersed the sections in serum for 10 minutes. Then all sections
were incubated at 4C overnight with the following antibodies:
mouse monoclonal antibody to b-catenin (1:100; Transduction Lab-
oratories, Lexington, Ky) and monoclonal antibody DO-7 (1:150;
DAKO, Glostrup, Denmark), which recognizes both wild-type
and mutant-type p53 proteins. Monoclonal antibody Ab-5 (1:20;
Oncogene, Boston, Mass), which recognizes only wild-type p53
protein, was also used to clarify the type of overexpressed p53.
Color reaction was performed by the labeled streptavidin biotin
technique with 3,30-diaminobenzidine as a chromogen (LSAB1
kit, HRP; DAKO). Tissues were counterstained with hematoxylin
and then dehydrated. Adjacent normal esophageal epithelium was
used as the internal control.
Evaluation of the immunohistochemical staining was conducted
by a pathologist who had no knowledge of the clinical characteris-
tics of the patients. The expression was scored as 3 if more than 75%
of tumor cells were immunostained positive, as 2 if 25% to 75% of
cells were positive, as 1 if less than 25% of cells were positive, and
as 0 if less than 5% were positive. The normal esophageal epithe-
lium was positively stained by b-catenin at the cell membrane but
negative for b-catenin in the cytoplasm and negative for p53/
DO-7 in the nucleus. On the basis of the normal epithelium expres-
sion, the membranous b-catenin expression was defined as reduced
if the score was 0, 1, or 2 and normal if the score was 3. Cytoplasmic
b-catenin expression was defined as increased if the score was 2 or 3
and normal if the score was 0 or 1. Four typical b-catenin expression
patterns were described and are shown in Figure 1. The p53 expres-
sion was defined as normal if the score was 0 or 1 and increased if the
score was 2 or 3. In the study, the p53 (Ab-5) antibody was
positively stained at the basal proliferative layer of normal esopha-
geal epithelium only, reflecting its role as cell cycle checkpoints at
G1 and G2 phase. The positive stain at the basal layer of normal
esophageal epithelium served as internal control.
Statistical Analyses
The correlations between immunohistochemical results and clinico-
pathologic variables were analyzed by c2 test. Survival curves were
estimated by the Kaplan–Meier method and compared by the log–
rank test. Multivariate analysis was performed by the Cox regression
model. Covariates were selected in a stepwise fashion withay 2008
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TSFigure 1. Immunohistochemical stain-
ing patterns of b-catenin in ESCC (orig-
inal magnification 3400). A, Preserved
b-catenin staining at the cell membrane
and normal staining in the cytoplasm. B,
Reduced staining at the cell membrane
and increased b-catenin staining in the
cytoplasm. C, Reduced b-catenin
staining at the cell membrane and no
staining in the cytoplasm. D, Preserved
b-catenin staining at the cell membrane
and increased staining in the
cytoplasm.Backward:Ward method. All calculations were performed with
SPSS 13.0 software (SPSS, Inc, Chicago, Ill).
Results
Table 1 shows the demographic data and the results of sur-
vival analysis in 68 patients with ESCC. The 5-year survival
was 23.5%, with a median survival of 20 months. Reduced
membranous b-catenin expression was noted in 43 (63.2%)
of 68 tumor specimens. Increased expression of cytoplasmic
b-catenin was noted in 15 (22.1%) of 68 specimens.
Increased protein expression of p53/DO-7 was observed in
43 (63.2%) of 68 specimens. None of the specimens stained
positively for wild-type p53 (Ab-5). In the survival analysis,
nodal involvement and distant metastasis were associated
with poor prognosis (P 5 .032 and .013, respectively).
Patients with reduced membranous b-catenin expression
had a worse prognosis than patients with normal membra-
nous b-catenin expression (Figure 2, P 5 .005). Patients
with increased p53 expression also had a worse prognosis;
however, the difference did not reach statistical significance.
In the combined analysis of membranous b-catenin and p53
protein expression in the prognostic significance of patients
with ESCC, we observed that patients with increased p53
and reduced membranous b-catenin protein expression had
the worst prognosis (Figure 3, P 5 .012). Table 2 showed
that there was no significant correlation between p53 and
membranous or cytoplasmic b-catenin protein expression in
ESCC specimens. Table 3 shows the relationship between
the clinicopathologic parameters and the immunohistochem-The Journal of Thoraical staining results. The results showed that reduced mem-
branous b-catenin expression was associated with the
presence of distant metastasis (P5 .006). There was no rela-
tionship between cytoplasmic b-catenin expression and any
T, N, or M factors. The increased p53 protein expression
correlated with lymph node involvement (P 5 .047). In
multivariate survival analysis, reduced membranous b-cate-
nin expression and nodal involvement were independent
prognostic factors (Table 4, P5 .004 and .019, respectively).
Discussion
In the present study, we showed for the first time, using
immunohistochemical analysis, that reduced membranous
b-catenin protein expression is associated with distant metas-
tasis and poor prognosis and that combined increased p53
and reduced membranous b-catenin protein expression are
indicative of a very poor prognosis in patients with ESCC.
In our study, 63.2% of tumor specimens had reduced b-cate-
nin staining in the cell membrane, which is compatible with
some previous reports in the literature.17-22 In contrast to our
study, Castro,17 Nair,18 and their colleagues found no corre-
lation between membranous b-catenin expression and any
clinicopathologic features including tumor grade and patient
survival. In Japan, Takayama,19 Nakanishi,20 and their asso-
ciates reported that although downregulation of membranous
b-catenin was associated with poor tumor differentiation,
membranous b-catenin expression did not have prognostic
significance in ESCC. In another study by Takayama and
coworkers,21 reduction in membranous b-catenin expressioncic and Cardiovascular Surgery c Volume 135, Number 5 1031
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Variable No. (%) Median survival (mo) Five-year survival (%) P value
Age .508
#65 years of age 32 (47.1) 23.00 6 7.01 25.0
.65 years of age 36 (52.9) 14.00 6 6.60 22.2
Sex .420
Male 66 (97.1) 20.00 6 4.5 22.7
Female 2 (2.9) — —
Tumor invasion depth (T) .142
T1/2 19 (27.9) 36.00 6 7.98 36.8
T3/4 49 (72.1) 15.00 6 4.08 18.4
Nodal involvement (N) .032*
N0 25 (36.8) 29.00 6 10.00 40.0
N1 43 (63.2) 15.00 6 2.18 14.0
Distant metastasis (M) .013*
M0 57 (83.8) 24.00 6 3.78 26.3
M1 11 (16.2) 11.00 6 1.65 9.1
Membranous b-catenin .005*
Normal 25 (36.8) 32.00 6 15.00 40.0
Reduced 43 (63.2) 14.00 6 2.73 14.0
Cytoplasmic b-catenin .821
Normal 53 (77.9) 20.00 6 4.68 24.5
Increased 15 (22.1) 24.00 6 8.373 20.0
p53 .276
Normal 25 (36.8) 32.00 6 6.50 32.0
Increased 43 (63.2) 15.00 6 1.87 18.6
Combined p53 and membranous b-catenin
Normal p53 and normal b-catenin 11 (16.2) 55.00 6 21.47 45.5 .012*
Increased p53 or reduced b-catenin 28 (41.2) 29.00 6 5.94 28.6
Increased p53 & reduced b-catenin 29 (42.6) 13.00 6 2.02 10.3
Median survival time is presented as an estimate 6 standard error of the mean. *A P value , .05 was considered significant by log–rank test.Figure 2. The Kaplan–Meier survival curve for protein expression
of membranous b-catenin, indicating that patients with reduced
membranous b-catenin protein expression had a poor prognosis
(log–rank test, P 5 .005).1032 The Journal of Thoracic and Cardiovascular Surgery c Mwas associated with the depth of tumor invasion and lymph
node involvement. In China, Zhao and colleagues22 reported
that there was a correlation between membranous b-catenin
expression and tumor histologic grade. Patients harboring
tumors with low membranous b-catenin expression had
shorter survival times than those with higher expression,
but the difference did not reach statistical significance in
that study. In our study, all 11 patients with distant metastasis
had reduced membranous b-catenin expression. In contrast,
none of patients with normal membranous b-catenin expres-
sion had distant metastasis. In a multivariate survival analy-
sis, reduced membranous b-catenin expression was also an
independent prognostic factor.
A possible explanation for the correlation between re-
duced membranous b-catenin expression and distant metasta-
sis may be disruption of cell–cell junction integrity. The
metastasis cascade includes steps of local invasion, intravasa-
tion, extravasation, and re-establishment at distant organs.23
In the initial steps of local invasion and intravasation, the can-
cer cells undergo the epithelial–mesenchymal transition,
which is a process that stable cell–cell and cell–matrix inter-
action was lost, and the tumor invasiveness was increased.24ay 2008
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loss of the adherens junction, which consists of b-catenin
and E-cadherin (E-cadherin–catenin complex).25 Following
the logic of this theory, it is intuitive that reduced membra-
nous b-catenin expression causes the dysfunction of the
E-cadherin–catenin complex, promotion of cancer cell
detachment from primary site, and facilitation of cancer
cell dissemination. The results of our study indicated that
membranous b-catenin is important in maintaining the
cell–cell junction in ESCC and that loss of membranous
b-catenin may contribute to enhanced tumor metastasis.
Cytoplasmic b-catenin is a member of the WNT pathway,
which had been investigated extensively in colorectal carci-
Figure 3. The Kaplan–Meier survival curve for protein expression
of p53 and membranous b-catenin, showing that combined in-
creased p53 expression and reduced b-catenin expression was
associated with a poor prognosis (log–rank test, P 5 .012).The Journal of Thornogenesis2-5; however, its role in ESCC tumorigenesis is
less clear. Authors of previous works have reported that
increased cytoplasmic b-catenin expression was found in
approximately 18% to 68% of ESCC.17,26,27 In the study
by Zhang and colleagues,26 which included 44 patients
with ESCC, the authors observed that increased cytoplasmic
b-catenin expression was associated with lymph node metas-
tasis. In another study, Shiozaki and associates27 showed that
patients with increased cytoplasmic b-catenin expression had
worse prognoses; however, in multivariate analysis, cyto-
plasmic b-catenin expression was not an independent signif-
icant prognostic factor in ESCC. In our study, increased
cytoplasmic b-catenin was noted in 22.1% of ESCC tumor
specimens. Cytoplasmic b-catenin protein expression was
not associated with any clinicopathologic parameters or
patient survival.
The clinical significance of p53 protein expression in
ESCC is controversial. In our study, increased p53 expres-
sion was observed in 63.2% of ESCC tumor specimens and
was associated with the nodal involvement. Although pa-
tients with increased p53 expression have a worse prognosis
than those with normal p53 expression, the difference did not
reach statistical significance. Some in vitro studies have re-
vealed cross-talk between b-catenin and p53. Accumulation
of b-catenin can serve as a stimulus for activation of p53
TABLE 2. Relationship between p53 and b-catenin
expression in the cell membrane and cytoplasm
p53
Normal Increased P value
Membranous b-catenin .345
Reduced 14 29
Normal 11 14
Cytoplasmic b-catenin .768
Increased 6 9
Normal 19 34TABLE 3. Relationship between clinicopathologic features and immunohistochemical staining results
Membranous b-catenin Cytoplasmic b-catenin p53
Reduced Normal P value Normal Increased P value Normal Increased P value
T .094 .901 .570
T1/2 15 4 15 4 8 11
T3/4 28 21 38 11 17 32
N .534 .768 .047*
N0 17 8 19 6 13 12
N1 26 17 34 9 12 31
M .006* .257 .163
M0 32 25 43 14 23 34
M1 11 0 10 1 2 9
Total 43 25 53 15 25 43
T, Tumor invasion depth; N, nodal involvement; M, distant metastasis. *A P value , .05 was considered significant by c2 test.acic and Cardiovascular Surgery c Volume 135, Number 5 1033
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other hand, activated p53 is able to enhance the expression
of Siah, Axin, and GSK3b proteins, which mediate the deg-
radation of the b-catenin protein.13-15 In one study based on
the Drosophila eye disc model, Yamaguchi and colleagues28
observed that mutation of the Armadillo (Drosophila b-cate-
nin) gene, which is essential for adherens junctions integrity,
leads to enhancement of p53-induced apoptosis, suggesting
that abnormality at the adherens junction is a signal for p53
activation and activated p53 consequently induces apoptosis
to remove abnormal cells from tissue. These interactions be-
tween b-catenin and p53, however, could not be confirmed
by immunohistochemistry methods in human cancers. In
hepatocellular carcinoma, Torbenson and associates29 found
no association between cytoplasmic b-catenin and p53
expression. In lung adenocarcinoma, Nozawa and col-
leagues30 concluded that there was no association between
membranous b-catenin and p53 expression. The relationship
between b-catenin and p53 has never been evaluated in
ESCC. In this study, we found no correlation between b-cat-
enin and p53 expression by using immunohistochemical
methods; however, we did show for the first time that com-
bined increased p53 and reduced membranous b-catenin
expression indicated a very poor prognosis in ESCC. Further
study to elucidate the relationship between membranous
b-catenin and p53 protein expression may be mandatory.
In conclusion, using immunohistochemical analysis, we
found that reduced membranous b-catenin protein expression
was associated with the presence of distant metastasis and
poor prognosis in ESCC. Combined increased p53 and
reduced membranous b-catenin protein expression indicated
a very poor prognosis in patients with ESCC. Further
TABLE 4. Multivariate survival analysis results
Variable Hazard ratio 95% CI P value
Tumor invasion depth .262
T1/2 1.00 —
T3/4 1.45 0.752–2.845
Lymph node involvement .019*
N0 1.00 —
N1 1.96 1.118–3.423
Distant metastasis .203
M0 1.00 —
M1 1.58 0.780–3.209
Membranous b-catenin .004*
Normal 1.00 —
Reduced 2.31 1.307–4.101
p53 .517
Normal 1.00 —
Increased 1.20 0.094–2.065
Multivariate analysis was performed by the Cox regression model. Covari-
ates were selected in a stepwise fashion with the Backward:Ward method.
Probability for stepwise was .05 for entry and .10 for removal, respectively.
CI, Confidence interval. *A P value , .05 was considered significant.1034 The Journal of Thoracic and Cardiovascular Surgery c Minvestigation is needed to understand the roles of b-catenin
and p53 in the tumorigenesis and metastasis of ESCC.
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